DNA methylation, non-coding RNAs, oncology, translational medicine, epigenetic therapy
cancer cell lines, mice models, patient samples
- Epigenetic profiling: Genome-wide characterization of CpG methylation (Illumina HiScanSQ technology); global analysis of methylcytosine content by HPLC-ESI/MS; ChIP on chip technology, MeDIP, analysis of histone marks in a cellular context (WB, ChiP, confocal microscopy,...), - Proteomic analysis. Quantitative proteomics (2D-DIGE, iTRAQ, SILAC) and Posttranslational modifications determination (CID and ETD fragmentation) - In vitro proliferation assays: MTT, colony formation assays, wound healing assay (in a panel of more than 150 cancer cell lines) - In vitro systems for genetic alterations: siRNA, genetic transfection - In vivo murine models (xenografts and patient derived xenografts),
We are in an institution devoted to translational research in biomedicine. In consequence, we reinforce collaboration with clinicians from National and International Medical Centers (mainly oncology but not restricted to). In previous FP7 and current H2020 projects, we also collaborate with experts in system biology and bioinfomaticians (analysis of *omics and algorithm’s development). Interaction with organic chemists is also frequent (epidrugs’s testing). Different SMEs help us with innovation and the technological transfer of our research.
Current research is aimed at the establishment of the epigenome maps of normal and transformed cells, the study of interactions between epigenetic modifications and non‐coding RNAs, and the development of new drugs for cancer. We are especially interested on the translational value of epigenetic research in oncology, so we are developing several projects together with private and public health services. Apart from oncology, we have specific projects in the area of: stem cell research, rare disorders associated with epigenetic defects (Sotos syndrome and Rett syndrome), metabolic diseases such as type-2 diabetes or neurological disorders (rare syndromes or Alzheimer disease).
• Associate Editor Clinical Epigenetics, • Member of the Ethics Committee of Bellvitge Hospital (evaluation of clinical trials). • Member of the Scientific Committee of Spanish National Association Against Cancer (AECC)